Growth Factors and Receptor Tyrosine Kinases in Development, Regeneration, and Tumorigenesis: 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 2046

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
Interests: growth factors; signal transduction mechanisms; receptors; kinases; angiogenesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Members of the family of receptor tyrosine kinases (RTKs) have been shown to have important functions in embryonal development, wound healing, and tissue homeostasis. Based on their structural properties, the 58 members of the family can be divided in 20 subfamilies; their extracellular ligand-binding parts are composed of different combinations of domains, including immunoglobulin-like, epidermal growth factor-like, fibronectin-like, cysteine-rich, cadherin-like, and discoidin-like domains, and their intracellular parts contain intrinsic tyrosine-kinase domains.

Many, maybe all, RTKs are activated by dimerization or oligomerization, induced by ligand binding. This results in the auto-phosphorylation of certain tyrosine residues in the intracellular parts of the receptors, creating docking sites for SH2-domain-containing molecules, as well as in the tyrosine phosphorylation of specific downstream signaling molecules. The activated signaling pathways leads to the stimulation of cell growth, survival, and migration. Over-activity, by mutation, amplification, or overexpression, of RTKs are common in tumorigenesis, and more than half of the known RTKs have been implicated as drivers of various types of tumors. Tyrosine kinase inhibitors have therefore been developed and are used clinically, with beneficial effects in the treatment of certain tumors.

This Special Issue will highlight recent developments in our understanding about the normal function of RTKs and their role in disease, as well as their structural properties.

Prof. Dr. Carl-Henrik Heldin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • receptor
  • tyrosine kinase
  • growth factor
  • signal transduction
  • development regeneration tumorigenesis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 1568 KiB  
Review
The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies
by Anh L. Nguyen, Caroline O. B. Facey and Bruce M. Boman
Cancers 2025, 17(1), 82; https://doi.org/10.3390/cancers17010082 - 30 Dec 2024
Cited by 1 | Viewed by 1882
Abstract
Fibroblast growth factors (FGFs) have diverse functions in the regulation of cell proliferation and differentiation in development, tissue maintenance, wound repair, and angiogenesis. The goal of this review paper is to (i) deliberate on the role of FGFs and FGF receptors (FGFRs) in [...] Read more.
Fibroblast growth factors (FGFs) have diverse functions in the regulation of cell proliferation and differentiation in development, tissue maintenance, wound repair, and angiogenesis. The goal of this review paper is to (i) deliberate on the role of FGFs and FGF receptors (FGFRs) in different cancers, (ii) present advances in FGF-targeted cancer therapies, and (iii) explore cell signaling mechanisms that explain how FGF expression becomes dysregulated during cancer development. FGF is often mutated and overexpressed in cancer and the different FGF and FGFR isoforms have unique expression patterns and distinct roles in different cancers. Among the FGF members, the FGF 15/19 subfamily is particularly interesting because of its unique protein structure and role in endocrine function. The abnormal expression of FGFs in different cancer types (breast, colorectal, hepatobiliary, bronchogenic, and others) is examined and correlated with patient prognosis. The classification of FGF ligands based on their mode of action, whether autocrine, paracrine, endocrine, or intracrine, is illustrated, and an analysis of the binding specificity of FGFs to FGFRs is also provided. Moreover, the latest advances in cancer therapeutic strategies involving small molecules, ligand traps, and monoclonal antibody-based FGF inhibitors are presented. Lastly, we discuss how the dysregulation of FGF and FGFR expression affects FGF signaling and its role in cancer development. Full article
Show Figures

Graphical abstract

Back to TopTop